scholarly journals Cell surface antigen expression by peripheral blood monocytes in allergic asthma: results of 2.5 years therapy with inhaled beclomethasone dipropionate

1996 ◽  
Vol 5 (5) ◽  
pp. 362-369
Author(s):  
W. A. T. Slieker ◽  
P. Th. W. van Hal ◽  
J. M. Wijkhuijs ◽  
J. P. M. Hopstaken-Broos ◽  
J. A. Noordhoek ◽  
...  
Keyword(s):  
Cell Surface ◽  
Allergic Asthma ◽  
Peripheral Blood ◽  
Beclomethasone Dipropionate ◽  
Blood Monocytes ◽  
Peripheral Blood Monocytes ◽  
Hla Dr ◽  
Long Term Treatment ◽  
Inhaled Glucocorticoids

At present, inhaled glucocorticoids are widely accepted as the therapy of choice in chronic asthma. Treatment with inhaled glucocorticoids significantly suppresses local airway inflammation in asthmatics, but may also have systemic effects, e.g. a reduction of the number of circulating hypodense eosinophils or a down-modulation of HLA-DR antigen (Ag) expression by T lymphocytes in peripheral blood. However, the effect of long-term therapy with inhaled glucocorticoids on peripheral blood monocytes (PBM), which are the precursors of the most numerous cell type in the lung, the alveolar macrophage, have not yet been evaluated. We therefore investigated the expression of various cell surface Ag on PBM from non-smoking patients with allergic asthma who were treated for 2.5 years with a β2-receptor agonist plus either an inhaled glucocorticoid (beclomethasone dipropionate, BDP) (n= 4) or an anticholinergic or placebo (n= 8). We compared the results with healthy volunteers (n= 7). Long-term treatment of allergic asthmatics with inhaled BDP, but not anticholinergic or placebo therapy, was associated with a significantly lower CDllb Ag expression (p< 0.04) and higher expression of CD13, CD14 and CD18 Ag (p< 0.05,p< 0.02 andp< 0.04, respectively) when compared with the healthy control subjects (n= 7). Most interestingly, PBM of asthmatics treated with inhaled BDP expressed an almost two-fold higher level of CD14 Ag on their cell surface than PBM of patients treated with anticholinergic or placebo (p< 0.03). No significant differences in the expression of CD16, CD23, CD25, CD32 and CD64 Ag or HLA-DR were observed between PBM from the different patient groups or healthy controls. Taken together, this study shows that long-term local therapy with inhaled BDP coincides with an altered expression of at least one cell surface Ag on PBM from allergic asthmatics.

Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer.

1995 ◽  
Vol 13 (9) ◽  
pp. 2324-2329 ◽  
Author(s):  
M Wiesenfeld ◽  
M J O'Connell ◽  
H S Wieand ◽  
N J Gonchoroff ◽  
J H Donohue ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Immune Function ◽  
Interferon Gamma ◽  
Peripheral Blood ◽  
Significant Enhancement ◽  
Blood Monocytes ◽  
Ifn Gamma ◽  
Peripheral Blood Monocytes ◽  
Hla Dr

PURPOSE The primary goal of this study was to assess the effectiveness of interferon gamma (IFN-gamma) to prevent tumor relapse following potentially curative surgery in patients with high-risk colon cancer. A secondary goal was to determine the effect of IFN-gamma on immune function and to correlate alterations in immune parameters with survival. PATIENTS AND METHODS Three to 4 weeks after undergoing resection of all known malignant disease, 99 patients with stage II, III, or IV colon cancer were randomly assigned to receive IFN-gamma 0.2 mg total dose by subcutaneous injection daily for 6 months or observation. Serial assessment of human leukocyte antigen (HLA)-DR expression and Fc receptors on peripheral-blood monocytes was conducted in 24 patients who received IFN-gamma and 27 control patients. RESULTS With a median follow-up duration of 59 months in patients still alive, there was evidence of a detrimental effect on time to relapse (P = .03) among patients who received IFN-gamma. There was no significant difference in patient survival (P = .12). This study has sufficient power to rule out a 25% reduction in death rate for patients who received IFN-gamma (P < .05). Significant enhancement of immune function was observed in patients treated with IFN-gamma as measured by HLA-DR expression (P < .01) and Fc receptors (P < .001) on peripheral-blood monocytes. CONCLUSION This study effectively rules out any clinically meaningful benefit for IFN-gamma as surgical adjuvant treatment for patients with high-risk colon cancer. Although significant enhancement of nonspecific immune function was seen with this dosage administration schedule of IFN-gamma, this was not associated with any demonstrable antitumor effect.

Long-term effect of full-mouth tooth extraction on the responsiveness of peripheral blood monocytes

2003 ◽  
Vol 30 (8) ◽  
pp. 756-760 ◽  
Author(s):  
Schelte J. Fokkema ◽  
Bruno G. Loos ◽  
Augustinus A.M. Hart ◽  
Ubele Van Der Velden
Keyword(s):  
Peripheral Blood ◽  
Tooth Extraction ◽  
Term Effect ◽  
Blood Monocytes ◽  
Peripheral Blood Monocytes ◽  
Long Term Effect

HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection

1991 ◽  
Vol 161 (6) ◽  
pp. 639-645 ◽  
Author(s):  
William G. Cheadle ◽  
Michael J. Hershman ◽  
Samuel R. Wellhausen ◽  
Hiram C. Polk
Keyword(s):  
Peripheral Blood ◽  
Antigen Expression ◽  
Blood Monocytes ◽  
Peripheral Blood Monocytes ◽  
Surgical Infection ◽  
Hla Dr

Low HLA-DR expression on peripheral blood monocytes predicts bacterial sepsis after liver transplantation: relation with prednisolone intake

1999 ◽  
Vol 1 (3) ◽  
pp. 146-152 ◽  
Author(s):  
J.W. Haveman ◽  
A.P. Van Den Berg ◽  
J.M.M. Van Den Berk ◽  
G. Mesander ◽  
M.J.H. Slooff ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Peripheral Blood ◽  
Blood Monocytes ◽  
Bacterial Sepsis ◽  
Peripheral Blood Monocytes ◽  
Hla Dr

scholarly journals Dependence of phenotype and chemiluminescent activity of monocytes on the Tregulatory cells content in patients with kidney cancer

2020 ◽  
Vol 22 (2) ◽  
pp. 347-356
Author(s):  
A. A. Savchenko ◽  
A. G. Borisov ◽  
I. V. Kudryavtsev ◽  
A. V. Moshev
Keyword(s):  
Kidney Cancer ◽  
Peripheral Blood ◽  
T Regulatory Cells ◽  
Relative Number ◽  
Control Group ◽  
Ros Production ◽  
Blood Monocytes ◽  
Peripheral Blood Monocytes ◽  
Inflammatory Monocytes ◽  
Hla Dr

The aim of this work was to reveal the interrelations between the number of T regulatory cells (Tregs) in patients with kidney cancer (KC) and phenotype of peripheral blood monocytes and their capacities to produce ROS. Patients with KC (T3N0M0, clear cell type) were examined prior to surgical treatment. Tregs phenotype and blood monocytes were identified by flow cytometry. ROS production of purified monocytes was carried out through the determination of lucigenin- and luminol-dependent spontaneous and zymosan-induced chemiluminescence activity. It has been found that the relative number of Tregs within total lymphocyte subset in KC patients was increased if compared to control values (in KC patients — Me = 6.3%). Then the patients were divided into two groups according to the median of Tregs number (less and more than 6.3%). The most pronounced changes in the phenotype of monocytes and their chemiluminescent activity were found in KC patients with the Tregs count of less than 6.3%. Our findings suggest that low frequency of Tregs in the periphery was associated with increased relative numbers of “intermediate” and “non-classical” (“pro-inflammatory”) monocytes as it was shown on the samples from patients with KC with a low level of Tregs. According to our data, both groups of KC patients had low levels of HLA-DR expression when comparing to control group. Furthermore, both groups of patients had decreased rates of HLA-DR and CD64 co-expressing cells. Changes in the phenotype of monocytes in patients with KC were closely linked with imbalance in ROS production. Thus, the monocytes spontaneous superoxide radical (primary ROS) synthesis in KC patients with a low Treg numbers were characterized by redused NADPH-oxidase activation time and increased level of its activity if compared to patients with a high Treg rates in peripheral blood. Next, the activation index for lucigenin-dependent chemiluminescence in KC patients was reduced, as well as it was independent of circulating Tregs rates and was determined apparently by the insufficiency of metabolic reserves. Similarly, spontaneous secondary ROS production by the monocytes in KC patients was lower then in healthy controls and was also independent of circulating Tregs rates. Finally, the induced secondary ROS synthesis and activation index for their synthesis in monocytes were reduced only in patients with KC with a low number of Tregs in the blood. In general, the characteristics of the chemiluminescent reaction of monocytes in patients with KC determined the imbalance in peripheral blood monocytes primary and secondary ROS production. Monocytes in patients with KC with a low number of Tregs in the blood were characterized by more pro-inflammatory activity due to the rapid activation and intensity of the synthesis of primary ROS.

Sign in / Sign up

Export Citation Format

Share Document